Astrazeneca PLC’s (AZN) Buy Rating Reaffirmed at Deutsche Bank AG
Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating reiterated by research analysts at Deutsche Bank AG in a research report issued on Friday.
Several other research analysts have also recently issued reports on AZN. Bank of America Corp. reaffirmed a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research report on Monday, July 18th. Beaufort Securities reissued a “hold” rating on shares of Astrazeneca PLC in a report on Tuesday, July 19th. Shore Capital reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 20th. TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, July 22nd. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $37.61.
Astrazeneca PLC (NYSE:AZN) opened at 27.68 on Friday. The company has a market capitalization of $70.03 billion, a PE ratio of 31.63 and a beta of 0.83. The company has a 50 day moving average of $30.74 and a 200 day moving average of $30.85. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.58. The business had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.95 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the firm posted $1.03 earnings per share. On average, equities research analysts forecast that Astrazeneca PLC will post $2.99 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. RDL Financial Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth about $532,000. Ngam Advisors L.P. increased its position in Astrazeneca PLC by 72.4% in the second quarter. Ngam Advisors L.P. now owns 440,868 shares of the company’s stock valued at $13,310,000 after buying an additional 185,089 shares during the period. Boyer & Corporon Wealth Management LLC increased its position in Astrazeneca PLC by 1.6% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 28,222 shares of the company’s stock valued at $852,000 after buying an additional 434 shares during the period. Becker Capital Management Inc. purchased a new position in Astrazeneca PLC during the second quarter valued at $35,701,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Astrazeneca PLC during the second quarter valued at $4,535,000. Institutional investors own 11.35% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.